13F Holdings
中文EN

RMTI ROCKWELL MEDICAL, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1041024 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.0%
TTM net income YoY-2.5%
TTM EPS YoY95.2%
Revenue 3-yr CAGR-3.5%
Net income 3-yr CAGR—

Margins

Gross margin18.1%
Operating margin-7.1%
Net margin-7.8%
FCF margin1.1%
EBITDA margin-4.6%

Returns

ROE-16.1%
ROA-9.9%
ROIC (approx.)-12.8%
Asset turnover1.27x

Leverage & solvency

Liabilities / assets42.0%
Debt / equity0.27x
Current ratio2.47x
Interest coverage-4.56x

Cash quality & payout

Operating cash flow / net income-0.47x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$69.26M$101.49M$83.61M$72.81M$61.93M
Cost of revenue$57.56M$84.00M$74.91M$68.73M$64.35M
Gross profit$11.70M$17.48M$8.70M$4.08M-$2.42M
R&D expense$0$19,000$1.11M$3.12M$6.83M
SG&A expense$14.03M$14.11M$12.14M$15.64M$15.35M
Operating income-$4.69M$608,000-$6.67M-$16.78M-$30.34M
Interest expense$1.12M$1.25M$2.30M$1.94M$2.36M
Pretax income-$5.31M-$480,000-$8.44M——
Income tax$0$0$0$0$0
Net income-$5.31M-$480,000-$8.44M-$18.68M-$32.67M
EBITDA-$2.50M$2.79M-$5.23M-$16.20M-$29.67M
EPS (basic)-0.15-0.03-0.37-1.31-3.83
EPS (diluted)-0.15-0.03-0.37-1.31-3.83
Weighted avg. shares (diluted)35.97M31.06M23.32M14.30M8.53M
Balance sheet
Cash & equivalents$10.71M$15.66M$8.98M$10.10M$13.28M
Short-term investments$14.29M$5.94M$1.95M$11.39M$9.16M
Receivables$8.14M$8.29M$10.90M$6.26M$5.91M
Inventory$3.42M$5.78M$5.87M$5.81M$4.08M
Current assets$38.16M$37.03M$28.77M$35.31M$35.29M
PP&E, net$4.63M$5.79M$6.40M$2.19M$2.49M
Goodwill$921,000$921,000$921,000$921,000$921,000
Intangibles$9.66M$10.21M$10.76M$0—
Total assets$57.15M$59.21M$52.17M$46.63M$48.57M
Current liabilities$9.58M$14.09M$16.64M$17.69M$20.97M
Short-term debt$0—$0$1.63M$7.38M
Long-term debt$8.83M$8.47M$8.29M$7.55M$13.19M
Total debt$8.83M$8.47M$8.29M$9.19M$20.57M
Total liabilities$20.16M$26.62M$30.88M$32.53M$46.04M
Shareholders' equity$36.98M$32.59M$21.29M$14.11M$2.54M
Net debt-$1.89M-$7.19M-$690,000-$916,000$7.29M
Shares outstanding3.94M34.06M29.13M12.16M8.54M
Cash flow statement
Operating cash flow-$659,000$4.20M-$9.41M-$16.93M-$33.53M
Capital expenditure$542,000$1.01M$284,000——
Free cash flow-$1.20M$3.19M-$9.70M——
Investing cash flow-$8.54M-$4.87M-$3.04M-$2.40M$311,000
Financing cash flow$4.25M$7.35M$11.34M$16.15M-$2.18M
Depreciation & amortization$2.19M$2.18M$1.44M$576,000$668,000
Stock-based compensation$1.82M$1.29M$932,000$315,000$943,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.